REYON Pharmaceutical Co., Ltd. (KRX:102460)

REYON Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,629	10,209	24,107	16,049	66,741	12,196
Short-Term Investments	-	-	-	20,000	30,380	32,900
Trading Asset Securities	12.74	6.05	134.02	19.83	327.64	371.8
Cash & Short-Term Investments	8,641	10,215	24,241	36,069	97,448	45,468
Cash Growth	9.43%	-57.86%	-32.79%	-62.99%	114.32%	-23.36%
Accounts Receivable	35,832	36,720	39,927	41,810	40,465	39,946
Other Receivables	216.64	442.44	50.98	238.02	384.38	3,768
Receivables	36,048	37,162	39,978	42,048	40,850	43,714
Inventory	35,177	41,991	35,176	30,109	26,432	28,438
Prepaid Expenses	135.28	28.03	229.57	28.53	32.51	33.16
Other Current Assets	14.16	47.67	188.61	751.89	41.89	120.34
Total Current Assets	80,016	89,443	99,813	109,006	164,804	117,774
Property, Plant & Equipment	371,683	384,397	368,342	340,568	281,156	170,971
Long-Term Investments	15,382	16,011	21,216	26,211	24,557	21,150
Other Intangible Assets	1,703	1,803	1,392	1,404	1,427	1,442
Long-Term Deferred Tax Assets	3,084	4,408	5,075	4,104	2,004	2,058
Long-Term Deferred Charges	2,800	2,800	2,800	2,800	2,800	2,800
Other Long-Term Assets	1,080	1,131	1,137	598.41	1,230	1,415
Total Assets	475,749	499,994	499,776	484,692	477,978	317,610
Accounts Payable	5,762	10,028	8,186	4,793	4,731	4,168
Accrued Expenses	3,410	3,513	3,776	3,646	2,253	1,793
Short-Term Debt	90,696	81,201	94,656	22,500	22,500	20,420
Current Portion of Long-Term Debt	10,000	8,000	6,000	-	-	-
Current Portion of Leases	1,108	1,458	1,610	2,254	1,911	2,571
Current Income Taxes Payable	-	-	852.4	733.48	426.48	297.61
Other Current Liabilities	19,615	31,336	10,522	14,025	15,682	19,504
Total Current Liabilities	130,592	135,537	125,602	47,951	47,503	48,754
Long-Term Debt	107,000	113,000	121,000	184,218	182,425	33,800
Long-Term Leases	46.58	392.9	1,788	1,231	478.19	2,644
Long-Term Deferred Tax Liabilities	-	65.84	12.95	-	7.09	-
Other Long-Term Liabilities	1,144	1,057	2,748	3,526	2,328	2,323
Total Liabilities	238,782	250,053	251,151	236,926	232,741	87,521
Common Stock	9,293	9,293	9,293	8,999	8,999	8,781
Additional Paid-In Capital	38,955	38,955	38,955	39,003	39,003	26,281
Retained Earnings	194,467	207,397	205,997	205,151	202,281	200,208
Treasury Stock	-5,079	-5,079	-5,079	-5,079	-5,079	-5,002
Comprehensive Income & Other	-669.64	-625.3	-541.75	-559.4	-217.03	-178.11
Total Common Equity	236,967	249,941	248,625	247,515	244,987	230,089
Shareholders' Equity	236,967	249,941	248,625	247,765	245,237	230,089
Total Liabilities & Equity	475,749	499,994	499,776	484,692	477,978	317,610
Total Debt	208,851	204,053	225,054	210,203	207,314	59,435
Net Cash (Debt)	-200,210	-193,838	-200,813	-174,134	-109,866	-13,967
Net Cash Per Share	-10915.98	-10568.57	-10948.85	-9538.14	-6200.33	-820.17
Filing Date Shares Outstanding	18.34	18.34	18.34	17.75	17.75	17.32
Total Common Shares Outstanding	18.34	18.34	18.34	18.25	17.75	17.67
Working Capital	-50,575	-46,093	-25,789	61,055	117,301	69,020
Book Value Per Share	12920.07	13627.46	13555.68	13560.43	13799.95	13023.92
Tangible Book Value	235,264	248,138	247,233	246,111	243,561	228,647
Tangible Book Value Per Share	12827.23	13529.15	13479.79	13483.51	13719.59	12942.27
Land	12,362	12,362	12,362	12,362	12,362	12,362
Buildings	209,537	209,537	12,712	12,712	12,712	12,712
Machinery	166,333	166,017	43,939	42,519	39,530	38,263
Construction In Progress	48,304	45,487	342,022	314,018	256,737	142,914

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.